Patterns of Care in Cancer Medicine - 2007 · Vol 4

AUDIO PROGRAM GUIDE

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Click here to download the entire program

Harold J Burstein, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts
Click here to download the entire interview

Track 1	Treatment of HER2-positive, node-negative tumors smaller than one centimeter
Track 2	Adjuvant docetaxel/carboplatin/trastuzumab (TCH)
Track 3	Concurrent versus sequential chemotherapy and trastuzumab
Track 4	Use of trastuzumab in the elderly
Track 5	Incidence of arthralgias associated with aromatase inhibitors (AIs)
Track 6	Management of arthralgias related to AIs
Track 7	Clinical use of the Oncotype DX™ assay
Track 8	Impact of Oncotype DX assay results on treatment decisions
Track 9	Treatment for premenopausal patients with ER-positive, early breast cancer
Track 10	Clinical trials evaluating ovarian suppression with aromatase inhibitors in premenopausal patients with ER-positive breast cancer
Track 11	Duration of adjuvant endocrine therapy


	Lee S Schwartzberg, MD Medical Director, The West Clinic Clinical Professor of Medicine University of Tennessee School of Medicine Memphis, Tennessee Click here to download the entire interview

Track 1	Second-line endocrine therapy for postmenopausal women with metastatic disease
Track 2	Nanoparticle albumin-bound (nab) paclitaxel versus other taxanes
Track 3	Use of premedications with taxanes
Track 4	Use of adjuvant docetaxel/cyclophosphamide (TC)
Track 5	Chemotherapy with bevacizumab for hormone-resistant metastatic disease
Track 6	TAnDEM trial data and treatment of hormone receptor-positive, HER2-positive, metastatic disease
Track 7	Anti-HER2 therapy for disease progression after adjuvant trastuzumab
Track 8	Bevacizumab combined with chemotherapy in the metastatic setting
Track 9	Controversies regarding the continuation of bevacizumab upon disease progression


	TOP OF PAGE \| PATTERNS OF CARE